CN Patent

CN108290824B — 索拉贝隆两性离子及其应用

Assigned to B3ar Therapy Co ltd · Expires 2022-03-11 · 4y expired

What this patent protects

本申请涉及对下尿路症状(如，例如，膀胱过度活动症和前列腺疾病)的治疗有用的索拉贝隆两性离子。此外，本申请涉及用于治疗下尿路症状的利用索拉贝隆两性离子的药物组合物和治疗方法。本申请还涉及从索拉贝隆两性离子制备索拉贝隆盐酸盐的方法。

USPTO Abstract

本申请涉及对下尿路症状(如，例如，膀胱过度活动症和前列腺疾病)的治疗有用的索拉贝隆两性离子。此外，本申请涉及用于治疗下尿路症状的利用索拉贝隆两性离子的药物组合物和治疗方法。本申请还涉及从索拉贝隆两性离子制备索拉贝隆盐酸盐的方法。

Drugs covered by this patent

vibegron (VIBEGRON)

Patent Metadata

Patent number: CN108290824B
Jurisdiction: CN
Classification: —
Expires: 2022-03-11
Drug substance claim: No
Drug product claim: No
Assignee: B3ar Therapy Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.